Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRSW107 in Pediatric Patients With Severe Hemophilia A
NCT06136507Phase 3Not yet recruiting
- Sponsor
- Gensciences
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor viii-fc fusion protein in hemophilia A, sponsored by Gensciences. Primary endpoint: Annualized Bleeding Rate at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
recombinant human coagulation factor viii-fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06136507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136507.